CardiaTec
AI-driven Multi-Omics Drug Discovery
CardiaTec
Drug Development
|
Cambridge, UK
About
CardiaTec develops validated drug candidates for coronary artery disease and acute coronary syndrome. Its proprietary machine-learning architecture combines scientific literature, structured databases and proprietary multi-omic data to generate novel drug targets.
Founders
Co-Investors
Laidlaw Scholars Ventures, o2h Ventures, Cambridge Enterprise
